Ligand Pharmaceuticals, Inc. - Ordinary Shares - Class B
LGND
Market Cap$2.2B
Close$
$79.76
31.1% downside
Current Fair Value
31.1% downsideOvervalued by 31.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.20 Billion |
|---|---|
| Enterprise Value | $2.17 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-0.22 |
| Beta | 0.71 |
| Outstanding Shares | 19,191,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -16.51 |
|---|---|
| PEG | 11.06 |
| Price to Sales | 12.86 |
| Price to Book Ratio | 2.82 |
| Enterprise Value to Revenue | 11.94 |
| Enterprise Value to EBIT | -61.34 |
| Enterprise Value to Net Income | -17 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Ligand Pharmaceuticals, Inc.
CEO: John Higgins